Signum Surgical ’s Post

Today we are delighted to announce that BioHealx has been granted marketing clearance by the U.S. Food and Drug Administration (FDA), as a first-of-its-kind medical device for the treatment of anal fistula. De Novo classification and clearance by the FDA is a key milestone for Signum Surgical and paves the way for bringing BioHealx to market for the benefit of patients, surgeons and the overall healthcare system.   To view the full press release, please visit: https://lnkd.in/eW2G3g2C   #MedTech #BioHealx #HealthcareInnovation #BioInnovate #SignumSurgical #FDA